How to Prepare Performance Verification Documentation for Overseas Registration of Dental Devices

When preparing performance verification documentation for overseas registration of dental devices, manufacturers must treat it as a comprehensive evidence chain—not a single test report. This evidence chain includes product technical requirements, test reports, environmental and stability studies, risk management reports, clinical evaluations or clinical evidence, and labeling. The first step is to confirm whether the target country regulates the product as a medical device, then determine the risk classification and corresponding registration pathway. Existing data from NMPA, CE, FDA, or ISO 13485 files can be reused, but must be locally adapted to GHWP member state guidelines, including differences in standard versions, test methods, and report formats.

Published: 2026-08-23 22:30 | Updated: 2026-08-23 22:30

Key Summary

For overseas registration of dental devices, performance verification documentation is the core evidence proving product safety and effectiveness and a key focus of technical file review in all countries. Manufacturers should first determine whether the target country regulates the product as a medical device, then confirm the registration pathway and application entity based on risk classification. Performance verification is not a single test report but a chain of evidence comprising product technical requirements, test reports, environmental and stability studies, risk management reports, clinical evaluations or clinical evidence, and labeling.

When NMPA, CE, FDA, or ISO 13485 documentation already exists, underlying test data and system evidence can be reused, but must be locally converted according to GHWP member state guidelines, including differences in standard versions, test methods, and report formats. Common risks include using a type-test report as a substitute for complete performance verification, ignoring laboratory qualifications or insufficient sample sizes, failing to re-verify after design changes, and not using post-market surveillance data for ongoing document updates.

Manufacturers should confirm regulatory requirements with local agents or authorized representatives early, establish a performance verification master file centered on risk management, and design a reusable structure of "base technical file + country-specific annexes" for multi-country registration. The local agent's management of certificate control, change notifications, and renewal responsibilities will directly affect the registration certificate lifecycle and market access stability.

Applicable Scenarios and Core Questions

Dental devices encompass a wide range of products, from single-use oral examination instruments, dental handpieces, and scalers to dental implants, dental CBCT, and intraoral scanners—all of which fall under medical device or related regulatory oversight. Before registering overseas, manufacturers must first clarify the scope and depth of performance verification documentation.

The scenario addressed in this article is when a manufacturer has decided to export dental devices to overseas markets but has not yet completed performance verification documentation, or already holds an NMPA registration certificate or CE certificate and wishes to reuse the documentation in other countries or regions. Here, "performance verification" is not simply a factory release test but a systematic evidence chain supporting product safety and effectiveness.

There are three core questions: first, what are the target market’s specific requirements for performance verification; second, whether existing test data can cover different registration requirements; and third, how to use limited resources to build a sustainable evidence maintenance system.

Registration Determination Logic

First, determine whether the product falls within the target country’s medical device regulatory scope. Not all dental devices are regulated as medical devices—for example, some brush heads or anti-caries materials may be regulated as cosmetics or ordinary consumer products. Manufacturers need to verify each product against the target market’s regulatory classification list.

Second, determine the risk level and registration pathway. In most GHWP member states, dental devices are classified from low to high risk as Class A, B, C, D or Class I, II, III. Low-risk products may only need to meet basic safety and performance requirements and submit a self-declaration or filing, while high-risk products such as implants and bone repair materials may require substantial equivalence arguments, clinical data, and even a quality system audit.

Third, identify the application entity. Most countries require a local registration holder (MAH) or authorized representative to submit the application. The manufacturer, as the provider of technical files, must sign an agreement with the local agent and clarify control of certificates, changes, and renewal responsibilities.

Fourth, assess whether existing documentation can be reused. NMPA registration certificates, CE technical documentation, FDA 510(k) or PMA materials, and ISO 13485 or MDSAP certificates can serve as a basis. However, each target market’s guidelines and standards must be compared item by item, especially performance indicators, test conditions, biological evaluation, and labeling requirements.

Fifth, confirm localization requirements. Language, local standards, measurement units, warning symbols, and agent information all need to be adjusted. GHWP member states have mutual recognition frameworks, but implementation details remain divergent; direct copying is not possible.

Documentation and Evidence

Performance verification documentation typically includes product technical requirements or specifications, test reports for key performance indicators, environmental testing and transport stability reports, software verification reports (if applicable), biocompatibility evaluation, electromagnetic compatibility reports, and electrical safety reports. For high-risk products such as dental implants, additional specific data such as fatigue testing and osseointegration evaluation are required.

Manufacturers should build on risk management in accordance with ISO 14971, establishing risk analysis and mapping risk control measures to performance indicators. Each performance indicator must have an acceptance criterion, a test method, and reliable raw data supporting it.

Clinical evaluation or clinical evidence is not required for all dental devices, but if intended use, contact duration, or implantation scenarios are involved, clinical trial evidence or literature review may be necessary. Clinical evaluation reports from CE or FDA submissions can be reused, but attention must be paid to the timeliness of clinical data and whether racial/population differences are accepted by the target market.

Labeling is part of performance verification documentation, not a separate legal text. Many countries treat labeling as an important part of registration review. Manufacturers must provide translations in the target language and ensure consistency with the technical parameters in the registration application.

If targeting multiple countries or GHWP multi-country registration, it is recommended to establish a Technical File Master, with country-specific differences as "Country Specific Annexes." This ensures consistency of underlying data and enables rapid conversion for different submissions, reducing repetitive work.

For devices that contact bone tissue, such as dental implants, orthodontic brackets, and CAD/CAM restorations, manufacturers must also prepare specialized verification data including mechanical properties, fatigue life, screw connection torque, and biological evaluation, and ensure that test samples are representative of the production batch.

Common Mistakes

The following are the most common mistakes manufacturers make when preparing performance verification documentation.

• Directly using NMPA type-test reports as performance verification data for all markets, ignoring target countries’ requirements on test standards, sample sizes, and validity periods.
• Conflating quality system audits with product performance verification, assuming that an ISO 13485 certificate eliminates the need for a separate performance verification report.
• Using third-party laboratories without proper qualifications, resulting in reports not being accepted by target country regulators.
• Lacking an evaluation procedure for product changes—when raw materials, processes, or suppliers change, old reports are still used for submission.
• Ignoring post-market surveillance feedback and failing to update performance verification documents with PMS data.
• Waiting to prepare technical files until after signing a local agent, which prolongs the application timeline and may miss market windows.

Preparation Checklist

Before initiating overseas registration, manufacturers should check each item on the following list.

• Confirm the target country and product classification, and identify the corresponding registration pathway, fees, and timelines.
• Perform a gap analysis of existing documentation, listing missing, expired, or non-recognized testing items one by one.
• Confirm with the target country’s local agent or consultant the specific performance verification requirements in regulatory guidelines.
• Establish a product performance master file, including design input, design output, verification, and validation records.
• If the product includes software, prepare software development lifecycle documentation and cybersecurity assessment records.
• Complete an ISO 14971 risk management report and maintain linkage between risk documents and performance testing.
• Commission testing from laboratories with ISO/IEC 17025 accreditation and retain raw records.
• Prepare labels, instructions for use, and packaging samples; complete translations and confirm alignment with registered technical parameters.

AIMEILI's Perspective

A common misjudgment is treating "performance verification documentation" as equivalent to a factory inspection report or a copy of test reports. In reality, overseas registration review requires a chain of evidence, not a single certificate. Reviewers pay more attention to whether tests were conducted by organizations complying with GLP/GCP principles, whether sample sizes are statistically meaningful, and whether test methods correspond to current versions of international standards.

At the early stage of a project, a registration gap analysis and pathway confirmation should be performed before rushing to pre-testing. Many companies start in the wrong direction, producing numerous test reports only to find that the target market does not recognize them, or that the product classification does not actually require such extensive verification. We first assess product risk class and applicable standards, then plan testing, which can save significant costs.

In existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation, underlying test data can usually be reused, but report formats, standard versions, audit evidence, and language must be localized. For example, CE test reports require EU notified body background; FDA accepts test data consistent with ASTM and ISO; GHWP member states each have their own acceptance criteria and format requirements. A simple seal or stamp is not sufficient.

The importance of local agents, certificate control, change management, and renewal is often underestimated. The registration certificate applicant is usually not the manufacturer but the local agent. If certificate control lies with the agent, a change in business relationships can cause the manufacturer to lose market access. We recommend clarifying certificate ownership, submission rights for changes, and renewal obligations in the cooperation agreement, and regularly auditing the agent’s compliance performance.

To reduce repetitive work and the risk of deficiency responses in multi-country registration, the most effective approach is to establish a "base technical file + country-specific annexes" structure. Common data should be placed in the master document, while country-specific regulatory differences, language, registration numbers, and agent information should be placed in annexes. If a deficiency is raised by any country during review, record it in the master document’s change history to avoid similar issues in other countries.

Frequently Asked Questions

What is the difference between performance verification and type testing?

Type testing is a complete inspection of samples according to product technical requirements, usually used for registration application or quality control. Performance verification is a broader evidence system that includes design verification, risk management, clinical evidence, and stability studies. A type-test report can be part of performance verification but cannot replace the complete performance verification logic.

Can the same performance verification report be shared for multi-country registration?

Underlying test data can be shared, but reports cannot be directly used across countries. Each country requires reports to comply with local regulatory requirements, including standard versions, test methods, report formats, laboratory qualifications, and validity periods. It is recommended to use the master technical file as the base and issue targeted summaries and declarations for each country.

Can performance verification be completed without clinical trial data?

If the product is low risk or substantially equivalent to an already marketed product, and clinical data can be obtained through literature, existing overseas clinical data, or equivalence analysis, then a new clinical trial is not required. However, high-risk implantable dental devices typically require direct clinical evidence. Manufacturers should communicate early with target country regulators or local consultants.

Does biocompatibility testing need to be redone?

If the product’s materials, manufacturing process, and contact duration have not changed, and the target country accepts the original laboratory data, then animal or cell testing does not need to be repeated. However, acceptance conditions vary by country. Some GHWP member states require reports from their recognized laboratories or additional testing for specific endpoints such as cytotoxicity, sensitization, and irritation.

Further Reading

Previous: What are the requirements for risk management documentation for overseas registration of dental devices?

Next: What are the requirements for risk management documentation for overseas registration of imaging equipment?

Recommended:

• How to prepare performance verification documentation for implantable product overseas registration?
• How to localize labels and instructions for monitoring equipment overseas registration?
• What are common reasons for deficiency responses in software medical device overseas registration?
• What are the requirements for risk management documentation for implantable product overseas registration?
• How to organize technical documentation for dental device overseas registration?
• Can dental device overseas registration test reports be reused?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundary

Author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory agencies, international organizations, standards bodies, and publicly available regulatory materials; industry media and project experience serve only as supporting judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of target country regulatory authorities, testing conclusions, or legal advice.